Tandem Diabetes Care, Inc. · NASDAQ:TNDM

Tandem Diabetes Care — Investor Day (September 2018)

126 slides from Tandem Diabetes Care's investor day presentation, Sep 25, 2018

1. Slide 1: Institutional Investor & Analyst Day

   Institutional Investor & Analyst Day September 25, 2018

2. Slide 2: Susan Morrison

   Susan Morrison EVP & Chief Administrative Officer SLIDE 2

3. Slide 3: Agenda

   AGENDA Welcome. Company Vision. Technology Roadmap and Product Innovation. Financial Outlook and International Expansion. INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 3

4. Slide 4: Safe Harbor

   SAFE HARBOR Cautionary Note Regarding Forward-Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation, statements about: the perceived advantages of our products relative to competitive products and technologies; our anticipated

5. Slide 5: Kim Blickenstaff

   Kim Blickenstaff President & CEO SLIDE 5

6. Slide 6: Strong short-term momentum, solid long-term growth

   Strong Solid short-term long-term momentum. growth trajectory. INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 6

7. Slide 7: Delivery Device Glycemic Control

   Delivery Device Glycemic Control INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 7

8. Slide 8: Expanding the market through innovation

   Expanding the market through innovation. INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 8

9. Slide 9: INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018

   INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 9

10. Slide 10: Domestic Global

    Domestic Global INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 10

11. Slide 11: Features and Clinical Outcomes

    Features Clinical Outcomes Touchscreen Remote Update Capability Dexcom® CGM Improving Reducing time in range and hypoglycemic events, A1c’s hospital visits and cost Discrete Discrete Rechargeable Battery Connectivity INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 11

12. Slide 12: $100 Million to $1 Billion Annual Sales

    $100 Million $1 Billion Annual Sales Annual Sales INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 12

13. Slide 13: Domestic Durable Pump Launches & Exits

    Domestic Durable Pump Launches & Exits Manufacturer 2012 2013 2014 2015 2016 2017 2018 t:slim G4 t:slim X2 t:slim X2 t:slim t:slim X2 & t:flex with G5 Basal-IQ 530G 630G 670G Vibe G4 Exit Spirit Exit Combo Snap Exit INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 13

14. Slide 14: Tandem's Growth

    Tandem’s Growth. Updated 2018 Sales Guidance: $160,000 $150M - $158M $140,000 $120,000 Sales in 000’s $100,000 $80,000 $60,000 $40,000 $20,000 $0 2012 2013 2014 2015 2016 2017 2018 INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 * Reflects $89 debt repayment in Q3 2018. SLIDE 14

15. Slide 15: Cadence of annual new product launches

    Cadence of annual new product launches. Growing the worldwide insulin pump market and capturing share. Increasing leverage. Reducing losses. Debt free. SLIDE 15

16. Slide 16: John Sheridan

    John Sheridan EVP & Chief Operating Officer SLIDE 16

17. Slide 17: Tandem mission statement

    Tandem Diabetes Care® is dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 17

18. Slide 18: Tandem mission statement

    Tandem Diabetes Care® is dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 18

19. Slide 19: First. Fast. Smart. Customer Focused.

    First. Relentless Fast. Innovation Smart. Customer Focused. INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 19

20. Slide 20: First

    First Touch screen. Rechargeable battery. Remote updateable software. Designation as compatible with iCGM. Part of an automated insulin delivery system requiring no finger sticks. INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 20

21. Slide 21: Fast

    Fast INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 21

22. Slide 22: Smart

    Smart Reliability & manufacturing efficiencies. Internal development processes. Automation. Partnerships. Lean R&D investment. INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 22

23. Slide 23: Customer Focused

    Customer Focused Easy to use. Look and feel like a consumer device. Software updatable. #1 rated customer service. INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 23

24. Slide 24: Technology Roadmap

    Regulatory strategy. Technology Automated insulin delivery. Roadmap Connected health. INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 24

25. Slide 25: Interoperability is changing the regulatory landscape

    Interoperability is changing the regulatory landscape. INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 25

26. Slide 26: Historical PMA system approval

    Historical PMA AID CGM Pump system approval. Algorithm CGM change required new PMA, new clinical data. New system CGM AID Pump approved. Algorithm INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 26

27. Slide 27: iCGM designation = no new PMA

    iCGM AID Pump Algorithm System approved for any iCGM iCGM designation = no new PMA. Labeling Update iCGM AID Pump Algorithm INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 27

28. Slide 28: iPump designation = no new PMA

    iCGM AID iPump Algorithm iPump designation = no new PMA. Labeling Update iCGM AID iPump Algorithm INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 28

29. Slide 29: Algorithm change requires new PMA

    iCGM iPump Algorithm change requires new PMA, AID new clinical data. Algorithm CGM iPump INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 29

30. Slide 30: Interoperable systems with multiple companies' devices

    Interoperable systems can include devices from multiple companies. Business agreements define product development, product support & financial terms. INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 30

31. Slide 31: Updated Regulatory Strategy

    Previously planned to file a Updated modular PMA in September. Regulatory Now submitting an application for an interoperable pump as part of Strategy an AID System (iPump). Followed by a PMA submission for the AID algorithm. No change to launch goal of Summer 2019. t:slim X2 with Control-IQ Technolo

32. Slide 32: Escalating t:sport development

    Escalating t:sport development. INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 32

33. Slide 33: The Evolution of t:sport

    The Evolution of t:sport First Final Market Advanced Concept Formative Hardware Research Prototyping Refinement Study Design 2009 2010-2012 2013-2015 2016-2017 2018 INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 33

34. Slide 34: Love Your Tubing

    Love Your Tubing. Freedom to disconnect. Reduce insulin waste if and when adhesives fail. Preserves current reimbursement model. INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018

35. Slide 35: t:sport features

    Small Pump with Tubing Mobile Control Bolus Button Multiple Infusion Set Options 200 Unit Syringe Cartridge 200 u Quick & Easy Fill Process Syringe Delivery AID Algorithm iCGM Integration Bluetooth® Radio ® Wireless Charging Updateable Optional Adhesive Sleeve Ability to Disconnect from Site Water R

36. Slide 36: t:sport control and FDA submission

    Controlled using a mobile app or a separate touchscreen controller. FDA submission as an iPump enabling use of Control IQ with no new clinical data. Launch goal: 2H 2020. INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 36

37. Slide 37: Automated Insulin Delivery

    Automated Insulin Delivery SLIDE 37

38. Slide 38: Predictive Low Glucose Suspension: What, Why, How, and Who?

    Predictive Low Glucose Suspension : What, Why, How, and Who? LAUREL H. MESSER, RN, MPH, CDE SENIOR INSTRUCTOR, BARBARA DAVIS CENTER, UNIVERSITY OF COLORADO

39. Slide 39: Disclosures for Laurel Messer

    Disclosures for Laurel Messer  Contract Certified Product Trainer for Medtronic  Received speaking honoraria from Tandem Diabetes Care  Consultant: Tandem Diabetes, Capillary Biomedical, Clinical Sensors

40. Slide 40: Predicted Low Glucose Suspend: What, Why, How and Who?

    Predicted Low Glucose Suspend: What, Why, How and Who? What is PLGS? Why do we need it? How does it work? PROLOG study results Patient experience

41. Slide 41: Why suspend insulin?

    Why suspend insulin? HYPOGLYCEMIA– glucose levels dangerously low SEVERE HYPOGLYCEMIA: United States registry data: o 11.8% adults experienced severe hypo in past 12 months1 o 6% Loss of consciousness or seizure in past 3 months2 o Higher risk: ◦ Higher age2 ◦ Longer diabetes duration1,2 ◦ Insulin

42. Slide 42: Nocturnal Hypoglycemia

    Nocturnal Hypoglycemia The overnight period is a particularly dangerous time for hypoglycemia. Sleep impairs hypoglycemia counter-regulation. Many individuals with T1D have impaired awareness of hypoglycemia.

43. Slide 43: Hypoglycemia: How to prevent?

    Hypoglycemia: How to prevent? Automated insulin systems Insulin delivery that is responsive to glucose levels Insulin delivery Glucose sensor Algorithm changed

44. Slide 44: Automated Insulin pathway

    Automated Insulin pathway Insulin delivery Glucose sensor Algorithm changed Kowalski, Diabetes Care 38: 1036-1042, 2015

45. Slide 45: Automated Insulin pathway

    Automated Insulin pathway Insulin delivery Glucose sensor Algorithm changed Kowalski, Diabetes Care 38: 1036-1042, 2015

46. Slide 46: t:slim X2 with Basal-IQ Technology

    t:slim X2™ with Basal-IQ™ Technology Insulin delivery Glucose sensor Algorithm changed Kowalski, Diabetes Care 38: 1036-1042, 2015

47. Slide 47: Predictive Low Glucose Suspend (PLGS)

    Predictive Low Glucose Suspend (PLGS) 1) Sensor glucose levels falling… 2) Algorithm predicts hypoglycemia in future 3) Insulin pump stops delivering insulin Insulin delivery Glucose sensor Algorithm changed

48. Slide 48: CGM and Reference Glucose Values and Insulin Infusion Rates

    CGM and Reference Glucose Values (top) and Insulin Infusion Rates (bottom) Figure 1. PLGS Example Patient (TAND1-001-0001): 2 CGM = YS! & Ins Challenge =x MBG + Suspend o* Resume © Carbs rp 00ZL r O0:bb y 00-01 y 00:60 y 00:80 r 00:40 r 00-6L ~ 00:8b 300 7 T fo} ire} a T T i=} i=} ie} wo a + OHO 6 1

49. Slide 49: Predicted Low Glucose Suspend: What, Why, How and Who?

    Predicted Low Glucose Suspend: What, Why, How and Who? What is PLGS? Why do we need it? How does it work? PROLOG study results Patient experience

50. Slide 50: PROLOG: PLGS for Reduction of Low Glucose

    PROLOG: PLGS for Reduction of Low Glucose Pivotal trial for PLGS Design: 6-week crossover RCT (3 weeks control, 3 weeks PLGS) o Control Arm: t:slim X2™ pump with commercially approved features and a Dexcom G5® CGM. o Experimental Arm: t:slim X2 pump with Basal-IQ™ PLGS feature. Multi Center study

51. Slide 51: Summary of PROLOG study

    Summary of PROLOG study Significant reduction in hypoglycemia with PLGS (all metrics) 31% relative reduction in mean time <70 mg/dl Greater effect in participants with greater baseline hypoglycemia Safety o No safety issues o No increase in mean glucose or hyperglycemia System suspensions of in

52. Slide 52: Predicted Low Glucose Suspend: What, Why, How and Who?

    Predicted Low Glucose Suspend: What, Why, How and Who? What is PLGS? Why do we need it? How does it work? PROLOG study results Patient experience

53. Slide 53: t:slim X2 with Basal-IQ

    t:slim X2 with Basal-IQ TM TM No fingersticks: Dexcom G6® glucose sensor o No fingersticks for calibration o No fingersticks needed for insulin dosing Minimal alerts o Prevents hypoglycemia without disruption

54. Slide 54: Basal-IQ What should patients expect?

    Basal-IQ What should patients expect? TM: Better quality of life Less worry about hypoglycemia, especially in overnight period Requires little to no BG tests (no calibration and approved to dose insulin based on SG value)

55. Slide 55: Summary

    Summary Hypoglycemia is a common problem for people with T1D Basal-IQ (PLGS) can reduce occurrences of hypoglycemia (31% in PROLOG study) High user satisfaction– no fingersticks, minimal alarms, easy to use PLGS is important step in Automated Insulin Delivery pathway

56. Slide 56: Automated Insulin

    Automated Insulin Automated Insulin is the future of insulin pumps and CGMs Insulin delivery Glucose sensor Algorithm changed

57. Slide 57: Thank you!

    Thank you! Laurel.Messer@ucdenver.edu

58. Slide 58: Our Path to Automated Insulin Delivery

    Our Path to Automated Insulin Delivery Patrick Keith-Hynes, PhD Chief Science Officer TypeZero Technologies Inc Tandem Diabetes Care September 25, 2018

59. Slide 59: Outline

    OUTLINE • Brief History of TypeZero Algorithm • inControl System • Studies and Results © TypeZero 2018

60. Slide 60: Automated Insulin Delivery - The Beginning

    AUTOMATED INSULIN DELIVERY - THE BEGINNING

61. Slide 61: Background

    BACKGROUND Core technology is based on 10+ years of R&D All developed with Dexcom CGM NIH, JDRF, UVA, Helmsley have invested more than $40 million to date 30 clinical studies 450 patients > 300,000 hours of use in human trials

62. Slide 62: Algorithm Lineage - Academia to Industry

    ALGORITHM LINEAGE - ACADEMIA TO INDUSTRY 2017 - Present 2016 2015 NIH-4: inControl - UVA Project 2014 JDRF-3: 6Nightlight 11-month month overnight andtest of 2013 24/7 CLC evening/overnight at home vs 24/7 CLC 2012 HCT-3: Summer camp study of 1- 2011 HCT-2: Summer weekcamp CLC,study of 5-UVA Stanfor

63. Slide 63: inControl Overview

    AUTOMATED INSULIN DELIVERY inControl Overview Robust, exhaustively tested modular algorithmic stack Improved glycemic time in range with dramatically reduced hypoglycemia Highly differentiated User Experience with best of class CGM September 25, 2018

64. Slide 64: inControl Features

    AUTOMATED INSULIN DELIVERY inControl Features Modular Closed Loop Control increases glycemic time in range while dramatically reducing hypoglycemia System automatically and smoothly decreases insulin infusion rate based on predicted hypoglycemic risk Automatically modulates basal infusion and genera

65. Slide 65: Core Concepts

    CORE CONCEPTS • Metabolic State Estimation • Quantitative Risk Assessment

66. Slide 66: Algorithm - Control Loop

    ALGORITHM - CONTROL LOOP Blood State Glucose Estimation Prediction CGM Core 5-minute Retrieve Data Quantitative Cycle CGM, insulin Pre- Risk history Processing Assessment Insulin Pump Dosing Algorithms Measure > Model > Predict > Act > Repeat

67. Slide 67: Algorithm Modules

    ALGORITHM MODULES Basal Attenuation Module smoothly reduces basal insulin delivery in response to predicted hypoglycemia } Hypo Safety Basal Increase Module manages increased basal rate in response to hyperglycemia prediction Hyperglycemia Correction Module delivers periodic automated correction bol

68. Slide 68: Results from Overnight Intensive Insulin Therapy

    RESULTS FROM OVERNIGHT INTENSIVE INSULIN THERAPY Sensor-Augmented Pump (SAP), mean; quartiles Control-to-Range (CTR), mean; quartiles 250 Blood Glucose Level (mg/dl) 200 150 100 Time of Day (h) 23:00 01:00 03:00 05:00 07:00 Brown, Kovatchev et al, Diabetes Technology and Therapeutics, 2015

69. Slide 69: Algorithm Performance - Stanford Summer Camp

    ALGORITHM PERFORMANCE - STANFORD SUMMER CAMP Publication Ly, Buckingham et al, Diabetes Care, 2016 Structure 24/7 - 17 subjects, 85 days and nights 24/7 Time 70-180 mg/dl 78.6% 24/7 Time below 70 mg/dl 1.8%

70. Slide 70: Algorithm Performance - Month Home Use

    ALGORITHM PERFORMANCE - 6 MONTH HOME USE Kovatchev, Cheng et al, Diabetes Technology and Therapeutics, Publication Vol 19 Number 1 2017 Structure 24/7 - 14 subjects, 6 months at home 24/7 Time 70-180 mg/dl 77% 24/7 Time below 70 mg/dl 1.3%

71. Slide 71: iDCL Trial

    IDCL TRIAL - NIH UC4 DK 108483 (2016-19) Primary Outcome: • Time < 70 mg/dl with non-inferiority for time above 180 mg/dl the International Secondary Outcomes: Diabetes Closed • hba1c, technology acceptance Loop (iDCL) Trial Objectives: University of Virginia • Establish Closed Loop Control as a via

72. Slide 72: Key Takeaways

    KEY TAKEAWAYS TypeZero algorithm is robust and exhaustively tested Improved glycemic time in range with dramatically reduced hypoglycemia Highly differentiated User Experience with best of class Dexcom CGM

73. Slide 73: Thank You

    t) typezero THANK YOU

74. Slide 74: Control-IQ Technology: Automated Insulin for Better Glycemic Control

    Control-IQ Technology: Automated Insulin for Better Glycemic control LAUREL H. MESSER, RN, MPH, CDE SENIOR INSTRUCTOR, BARBARA DAVIS CENTER, UNIVERSITY OF COLORADO

75. Slide 75: Control IQ: Automated insulin for better glycemic control

    Control IQ: Automated insulin for better glycemic control Why do we need Control-IQ? How does it work? Ongoing studies Patient experience

76. Slide 76: Glycemic control

    Glycemic control Hypoglycemia Hyperglycemia 2015 data on overall glycemic control in United States ADA/JDRF A1c Cutoffs

77. Slide 77: How to improve overall glucose control?

    How to improve overall glucose control? Automated insulin systems Insulin delivery that is responsive to glucose levels Insulin delivery Glucose sensor Algorithm changed

78. Slide 78: Automated Insulin pathway

    Automated Insulin pathway Insulin delivery Glucose sensor Algorithm changed Kowalski, Diabetes Care 38: 1036-1042, 2015

79. Slide 79: Control-IQ: Automated Insulin delivery

    Control-IQ: Automated Insulin delivery Insulin delivery Glucose sensor Algorithm changed OK glucose  Programmed insulin Low glucose  Less insulin High glucose  More insulin

80. Slide 80: Control IQ: Automated insulin for better glycemic control

    Control IQ: Automated insulin for better glycemic control Why do we need Control-IQ? How does it work? Ongoing studies Patient experience

81. Slide 81: Control-IQ put to the test

    Control-IQ put to the test 2017: Preliminary studies in adults with T1D 2018: Preliminary studies in children with T1D Current: Control-IQ Pivotal trial in adults and adolescents with T1D

82. Slide 82: 2018: Control-IQ ski camp

    2018: Control-IQ ski camp 3 days/2 nights in Breckenridge, Colorado 12 children ages 6-12 with T1D Randomized: ½ control group, ½ Control-IQ group Went home for three days wearing system

83. Slide 83: Results of Ski Camp

    Results of Ski Camp Everyone had fun! No one broke any bones! System performed very well… … But that’s all I can say

84. Slide 84: Current Control-IQ pivotal trial

    Current Control-IQ pivotal trial Clinical Trials NCT03563313 6 month RCT comparing Control-IQ with standard insulin pump and sensor Ages 14-75 years old 168 participants Outcome: Time in glucose range 70-180 mg/dl

85. Slide 85: Control-IQ Technology: Automated insulin for better glycemic control

    Control-IQ Technology: Automated insulin for better glycemic control Why do we need Control-IQ? How does it work? Ongoing studies Patient experience

86. Slide 86: t:slim X2 with Control-IQ

    t:slim X2 with Control-IQ TM TM Technology acceptance comes down to: o Usefulness o Ease of Use Technology acceptance Ease of Use Usefulness

87. Slide 87: t:slim X2 with Basal-IQ

    t:slim X2 with Basal-IQ TM TM HIGH EASE OF USE No fingersticks: Dexcom G6® glucose sensor o No fingersticks for calibration o No fingersticks needed for insulin dosing Minimal alerts o Prevents hypoglycemia without disruption Remote software updating (new versions, new functionality, etc.)

88. Slide 88: t:slim X2 with Control-IQ

    t:slim X2 with Control-IQ TM TM HIGH USEFULNESS Assistance mitigating HIGH and LOW glucose levels Expect more glucose levels in target range

89. Slide 89: What are our study patients saying?

    What are our study patients saying? Sleeping through the night for the first time since diagnosis Not having to interrupt life to test glucose levels and treat low/high glucose levels Feeling safer driving, working, etc. Better glucose control with exercise

90. Slide 90: Thank you!

    Thank you! Laurel.Messer@ucdenver.edu

91. Slide 91: Reducing Patient Interaction

    Reducing Patient Interaction Predictive Hybrid Fully Low Advanced Closed Closed Glucose HCL Loop (HCL) Loop Suspend 2018: Basal-IQ 2019: Control-IQ No carb counting Bolus automation. technology. technology featuring for meals. automated correction Personalized boluses.* settings. INVESTOR & ANALYST

92. Slide 92: Xavier de Anda

    Xavier de Anda Director, Connected Health SLIDE 39

93. Slide 93: Connected Health at Tandem

    Connected Health at Tandem. To produce value-driven innovation throughout the entire diabetes healthcare ecosystem. INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 40

94. Slide 94: Diabetes Management Application

    Diabetes Management Application INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 41

95. Slide 95: Mobile

    Mobile A Foundation for Remote Control Wireless pump uploads. • . Secondary pump display. Health app integration. Diet, sleep & exercise integration. Personalization. Decision support. Biometric authentication. INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 42

96. Slide 96: Ecosystem Expansion

    Ecosystem Expansion Support pump roadmap. Remotely control pump. Smartwatch technology. Data analytics. INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 43

97. Slide 97: Amassing Useful Data

    Billions of data points. Insulin, CGM, carbs, site change, pump utilization, Amassing BG, bolusing. Useful Data 3.7M cumulative days of combined CGM and insulin therapy data. INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 44

98. Slide 98: Providing customers flexible opportunities to engage with data

    Providing customers flexible opportunities to engage with data and HCPs and better self-manage their care. INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 45

99. Slide 99: Proven design philosophy

    Proven design philosophy. Simple, easy-to-use products that reduce customer burden and improve the experience. Rapid innovation. 6 product launches in 6 years. Committed to our goal of launching a new product each year. INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 46 46

100. Slide 100: Leigh Vosseller

     Leigh Vosseller EVP & Chief Financial Officer SLIDE 47

101. Slide 101: Strong short-term momentum

     Increased 2018 Sales Guidance Strong As of 2018 Sales 9/25/18 $150M - $158M 7/30/18 $140M - $148M short-term International Q318 Sales $7M - $8M $42M - $44M - - momentum International $2M - INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 48

102. Slide 102: Solid long-term growth trajectory

     Solid Product pipeline. long-term Renewals. growth Animas conversions. trajectory International. INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 49

103. Slide 103: Brian Hansen

     Brian Hansen EVP & Chief Commercial Officer SLIDE 50

104. Slide 104: People with type 1 and type 2 diabetes in the US

     Approximately 1.7 million people live with type 1 diabetes in the United States. Approximately 1.6 million people who live with type 2 diabetes are candidates for pump therapy. INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 Source: Centers for Disease Control. Internal estimates. SLIDE 51

105. Slide 105: Approximately 70 sales territories

     Apx. 70 sales territories calling on healthcare prescribers and people with diabetes. INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 52

106. Slide 106: Domestic Insulin Pump Market Share by Manufacturer

     Domestic Insulin Pump Market Share by Manufacturer* Animas & Tandem and Others Tandem 8% Medtronic are the 12% remaining domestic Insulet Medtronic durable insulin pump 15% 65% manufacturers. INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 *Internal estimates SLIDE 53

107. Slide 107: Our customers

     Our customers. 90% have type 1. Wide age distribution. Equal mix of women and men. 50% previously used multiple daily injection; 50% converted from a different pump. 40% integrate with CGM. INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 All figures are approximations SLIDE 54

108. Slide 108: Designed for use with or without advanced features

     Designed for use with or without advanced features INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 55

109. Slide 109: t:slim X2 vs 670G customer survey

     (Top 2 Box 9 -10) t:slim X2 670G n=168 n=112 “My pump is 70% 38% easy to use” “Helps me have 60% 44% good BG control” “Helps me feel more in control 57% 39% of my diabetes” All comparisons between Top 2 box scores shown are statistically significant, p <.001 INVESTOR & ANALYST DAY | SEPTEMBER 25, 20

110. Slide 110: Pump therapy + CGM offers the greatest benefit

     Pump therapy + CGM offers the greatest benefit. INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 T1D Exchange Patient Registry (n=17,731) SLIDE 57

111. Slide 111: INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018

     INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 58

112. Slide 112: Reimbursement Opportunities

     Advocacy for choice. Fewer competitive pump offerings. Reimbursement Opportunities Financial position. Robust data – share in payor cost-savings. INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 59

113. Slide 113: Time in Range, Payor X Patient Examples

     Payor X Patient Examples from t:connect 100% 94% 90% 90% 82% 78% Time in Range (70-180mg/dl) 80% 74% 75% 69% 69% 70% 56% 59% 60% 55% 50% 46% 40% 30% 20% 10% 0% Patient A Patient B Patient C Patient D Patient E Patient F Before Basal-IQ After Basal-IQ INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 Note:

114. Slide 114: Goal: Grow U.S. pump market penetration to more than 50%

     Goal: Grow the U.S. pump market from less than 30% penetration to more than 50%. 550K 900K Pumpers 350K New Pumpers (28% T1D Pumpers (50% T1D Penetration) Penetration) INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 61

115. Slide 115: People with type 1 diabetes outside the US

     Apx. 42.5 million people OUS with type 1 diabetes. Source: International Diabetes Federation, 2017 INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 62

116. Slide 116: Type 1 diabetes in long-term target markets outside the US

     Approximately 3 million people live with type 1 diabetes in our long-term target markets outside the United States. INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 Source: internal estimates. SLIDE 63

117. Slide 117: Our international pump capture opportunity

     550,000 pumpers OUS Our international 300,000 pumpers in long-term target pump capture markets opportunity. 150,000 pumpers in near-term target markets INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 Source: American Diabetes Association and internal estimates. SLIDE 64

118. Slide 118: Distributor support differs by geography

     Tandem’s involvement to support distributors differs in the U.S., Canada, and in other geographies OUS. INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 65

119. Slide 119: 5-Year Installed Base Goals

     5-Year Installed Base Goals: Domestic: Nearly triple from 66,000 today to more than 175,000 customers. International: Grow to more than 50,000 customers. INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 66

120. Slide 120: Reimbursement differs by product, per-patient amount similar

     Reimbursement differs by product but total amount realized per patient is approximately the same in a four-year reimbursement cycle. Domestic OUS % Distributor 80% 85% - 90% Pump $4K $2K - $3K 1 reimbursed every 4 years Supplies 120 cartridges and infusion sets $4K $5K used per patient per year Tota

121. Slide 121: Focus on Profitability

     Reimbursement. Sales volume. Focus on Product cost reduction. Profitability Managed expense growth. INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 68

122. Slide 122: Manufacturing Facility Capacity

     Manufacturing Facility Capacity Leverage Manufacturing Overhead Equipment Lines 2 4 Annual Units 110K 12M Installed Base Equivalent N/A 100K Additional On-Site N/A 2 lines Equipment Capacity INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 69

123. Slide 123: Expand Gross Margin

     Expand Gross Historical progress Margin driven by volume, efficiency & reliability. >60% 60% 55% Longer-term gross 50% margin driven by Q4 Gross Margin 40% reimbursement & 30% 20% new products, offset 10% by international. 0% 2017 2019 Goal INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 70

124. Slide 124: Manage Operating Expenses

     Manage Operating Expenses Long-term Average Annual Growth Rate R&D 10% SG&A 15% INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 71

125. Slide 125: Key Financial Milestones & Goals

     Key Financial Milestones & Goals >$100M First Annual 25%+ Cash Flow Cash and Positive EBITDA Operating Breakeven No Debt EBITDA Profit Margin Q3 2018 Q4 2018 2H 2019 2020 Long Term Goal Goal Goal Goal INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 72

126. Slide 126: INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018

     INVESTOR & ANALYST DAY | SEPTEMBER 25, 2018 SLIDE 73

Tandem Diabetes Care — Investor Day (September 2018) on 6ix